In court documents, BMS' counsel asserts that the 340B allows both upfront discounted sales and the rebate model proposed for Eliquis. And that means HRSA's decision last month to block the latter ...

Goldman Sachs analyst Salveen Richter highlights potential benefits for biopharma from 340B reforms, while Medicaid cuts could pose risks for companies with significant drug exposure.

Johnson & Johnson, Eli Lilly, Sanofi and Bristol Myers Squibb are suing the federal government over the future of their 340B drug rebate plans. The lawsuits reflect rising tensions among ...

Find this week’s updates on 340B litigation to help you stay in the know on how 340B cases are developing across the country. Each week we comb through the dockets of more than 50 340B cases to ...

As pharmaceutical companies push back against the 340B Drug Pricing Program, several states, including Utah, Colorado, Arkansas, Maine and Nebraska, are introducing legislation to protect the ...

On Friday, Johnson & Johnson (NYSE:JNJ) announced that it would implement significant changes to offering 340B pricing for ...

A US government agency has hit back at a plan by Johnson & Johnson to change the way it pays discounts on drugs to hospitals participating in the 340B programme for healthcare systems serving ...

Genentech sues federal government over 340B discounts to STD clinics, joining Amgen, Eli Lilly and UCB in challenging program ...

The 340B program, once a lifeline for underserved communities, has become a case study in crony capitalism. Designed to help hospitals serving low-income patients by offering discounted ...

Regarding “New Jersey hospitals exploit 340B at the expense of patients,” NorthJersey.com, Jan. 17: Everyone can relate to the high price of prescription drugs — including hospitals ...

Eli Lilly (NYSE:LLY) has filed a lawsuit over a U.S. health agency's alleged attempts to block its model for offering rebates for drugs supplied under the government's 340B Program, days after its ...

The federal 340B Drug Pricing Program allows certain hospitals and clinics to buy medications given to outpatients at a discount, then bill patients and insurers the full price — keeping the ...